Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/17/2023* -- Results Q4 2022 -- -0.45 --
02/17/2023* 16:30 EST Earnings Call Q4 2022 -- -- --
11/03/2022 -- Results Q3 2022 -0.97 -0.62 -56.70%
08/08/2022 -- Results Q2 2022 -0.88 -0.53 -66.77%
05/05/2022 -- Results Q1 2022 -0.78 -0.64 -22.28%
02/17/2022 16:30 EST Earnings Call Q4 2021 -- -- --
02/17/2022 -- Results Q4 2021 -0.71 -0.44 -62.83%
11/04/2021 -- Results Q3 2021 2.13 2.24 -4.70%
*Estimated Date/Time

Earnings

Next Report Date 02/17/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/03/2022
Beat/Miss Upgrade
Return Since -0.99%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
URL https://www.prothena.com
Investor Relations URL https://ir.prothena.com/
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Feb. 17, 2023 (est.)
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
-27.78%
-23.79%
-72.53%
53.69%
-24.13%
311.3%
21.96%
-5.20%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
6.11%
--
--
--
--
--
--
--
-1.94%
-22.43%
23.50%
-7.94%
20.43%
10.56%
-22.81%
25.05%
-2.35%
-37.40%
0.34%
-75.59%
-9.59%
-81.67%
-75.25%
-87.38%
-20.69%
--
--
--
-10.18%
-78.02%
-60.38%
-85.71%
44.05%
As of January 27, 2023.

Profile

Edit
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
URL https://www.prothena.com
Investor Relations URL https://ir.prothena.com/
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Feb. 17, 2023 (est.)
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
IBRN 191695.0 USD 3.54%
SBIO 1.847M USD 1.58%
QCSGX 8.503M USD 1.46%
QCSCX 11.57M USD 1.09%
FBIOX 47.61M USD 0.89%
IWC 4.399M USD 0.45%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter PRTA Tweets